Neyts Lab

To study Rift Valley fever virus (RVFV) pathogenesis & to develop inhibitors we established an infection model in zebrafish. RVF is a
WHO-listed priority disease, it causes haemorrhagic fever, encephalitis and blindness.

The dissemination of Rift Valley fever virus to the eye and sensory neurons of zebrafish larvae is stat1 dependent The Rift Valley fever virus (RVFV) is listed by the WHO as priority disease and causes haemorrhagic fever, encephalitis, and permanent blindness. To study RVFV pathogenesis and identify small-molecule antivirals, we established a novel in vivo model using zebrafish larvae. Pericardial injection of R...

Check our paper in Journal of Virology, in which we report on a robust SARS-CoV-2 infection model in SCID mice that is ideally suited to assess efficacy of small molecules.

A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection - PubMed Ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lacks the intrinsic ability to bind to the mouse ACE2 receptor, and therefore establishment of SARS-CoV-2 mouse models has been limited to the use of mouse-adapted viruses or genetically modified mice. Interestingly, some of the....

Het was een grote eer minister Petra De Sutter - naast politica ook arts en wetenschapper - te mogen ontvangen op het
Een boeiende discussie over (virale) infectieziekten en “pandemic preparedness”. Zeer motiverend bezoek voor gans het team.

Brincidofovir (TEMBEXA®) is FDA-approved & EMA orphan designation for treatment of smallpox. It is also effective in experimental models against monkeypox.
Almost 20 years ago, our laboratory laid the basis for this drug with the discovery of the anti-pox virus activity of cidofovir.

Tecovirimat (Tpoxx®) (SigaTech) is FDA and EMA-authorized for the treatment of poxvirus infections, including monkeypox. In 2005, our team -together with Viropharma- was the first to demonstrate activity of the drug against poxvirus infections in an animal model.

Our colleague Marc Van Ranst gives a clear explanation regarding at VRT news.

Wat zijn de symptomen van apenpokken en hoe komt virus hier terecht? Viroloog Van Ranst beantwoordt jullie vragen Viroloog Marc Van Ranst heeft vanmiddag in "Stel je vraag" enkele veel voorkomende vragen over de apenpokken beantwoord.

Our lab has contributed to this study of the Veesler laboratory (Seattle). An ultrapotent pan-variant antibody, unaffected by any Omicron lineage, was discovered. This could be an ideal candidate therapeutic antibody for the treatment of COVID-19.

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages SARS-CoV-2 Omicron sublineages carry distinct spike mutations and represent an antigenic shift resulting in escape from antibodies induced by previous infection or vaccination. We show that hybrid immunity or vaccine boosters result in potent plasma neutralizing activity against Omicron BA.1 and BA....

In this paper from our lab, we show that the anti-HIV drugs Lopinavir/Ritonavir & Nelfinavir result in a marked improvement of SARS-CoV-2-induced lung pathology in the hamster infection model (without an antiviral effect).

HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect Nelfinavir is an HIV protease inhibitor that has been widely prescribed as a component of highly active antiretroviral therapy, and has been reported …

Our lab, together with Aligos Therapeutics and CD3, has contributed to the development of a highly potent inhibitor of SARS-CoV-2 (targeting the viral protease) for oral treatment and prevention of COVID-19.

Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19, to Advance into Development | Aligos Therapeutics ALG-097558 demonstrates nanomolar potent antiviral activity and is up to 20-fold more active than nirmatrelvir in cell-based assays against multiple SARS-CoV-2 variants SOUTH SAN FRANCISCO, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc.

Presentations at

Posters at

Our team is present at , the international conference for antiviral research, in Seattle!